Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113) (BETADECLINE)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Type 2 Diabetes

Study type: Observational

Funder types: Industry

Identifiers

NCT01472341

0000-113

Details and patient eligibility

About

The purpose of this study is to evaluate the degree of beta-cell dysfunction among participants with type 2 diabetes and the association between beta-cell dysfunction and demographic, clinical, and treatment variables.

Enrollment: 507 patients

Sex: All

Ages: 41+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Physician diagnosis of type 2 diabetes mellitus by American Diabetes Association (ADA) criteria
• Oral hypoglycemic drug therapy for ≥1 year
• Continuous care at the clinic (at least 2 visits) for at least one year
• Medical records completed with a minimum core data set
• Completed consent form

Exclusion criteria

• Participation in a clinical trial in the previous 1 year
• Currently using insulin
• Type 1 diabetes
• Pregnancy

Trial design

507 participants in 1 patient group

All Participants

Description:

Participants receiving routine care under a diabetologist.